Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide

Sarath Vijayakumar, Frederic F. Depreux, Francine M. Jodelka, Jennifer J. Lentz, Frank Rigo, Timothy A. Jones, Michelle L. Hastings

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Usher syndrome type 1C (USH1C/harmonin) is associated with profound retinal, auditory and vestibular dysfunction. We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically improves auditory function and balance behavior inmice homozygous for the harmonin mutation Ush1c c.216G > A following a single systemic administration. The findings were suggestive of improved vestibular function; however, no direct vestibular assessment wasmade. Here, we measured vestibular sensory evoked potentials (VsEPs) to directly assess vestibular function in Ushermice. We report that VsEPs are absent or abnormal in Ushermice, indicating profound loss of vestibular function. Strikingly, Ushermice receiving ASO-29 treatment have normal or elevated vestibular response thresholds when treated during a critical period between postnatal day 1 and 5, respectively. In contrast, treatment ofmice with ASO-29 treatment at P15 was minimally effective at rescuing vestibular function. Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestibular recovery to support normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at P15 despite the profound vestibular functional deficits that persist with treatment at this later time. These findings provide the first direct evidence of an effective treatment of peripheral vestibular function in amouse model of USH1C and reveal the potential for using antisense technology to treat vestibular dysfunction.

Original languageEnglish (US)
Pages (from-to)3482-3494
Number of pages13
JournalHuman Molecular Genetics
Volume26
Issue number18
DOIs
StatePublished - Sep 2017

Fingerprint

Usher Syndromes
Antisense Oligonucleotides
Evoked Potentials
Technology
Mutation
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Genetics(clinical)

Cite this

Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide. / Vijayakumar, Sarath; Depreux, Frederic F.; Jodelka, Francine M.; Lentz, Jennifer J.; Rigo, Frank; Jones, Timothy A.; Hastings, Michelle L.

In: Human Molecular Genetics, Vol. 26, No. 18, 09.2017, p. 3482-3494.

Research output: Contribution to journalArticle

Vijayakumar, Sarath ; Depreux, Frederic F. ; Jodelka, Francine M. ; Lentz, Jennifer J. ; Rigo, Frank ; Jones, Timothy A. ; Hastings, Michelle L. / Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide. In: Human Molecular Genetics. 2017 ; Vol. 26, No. 18. pp. 3482-3494.
@article{0dba79a0fa574c50afcfd8fe2cf47306,
title = "Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide",
abstract = "Usher syndrome type 1C (USH1C/harmonin) is associated with profound retinal, auditory and vestibular dysfunction. We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically improves auditory function and balance behavior inmice homozygous for the harmonin mutation Ush1c c.216G > A following a single systemic administration. The findings were suggestive of improved vestibular function; however, no direct vestibular assessment wasmade. Here, we measured vestibular sensory evoked potentials (VsEPs) to directly assess vestibular function in Ushermice. We report that VsEPs are absent or abnormal in Ushermice, indicating profound loss of vestibular function. Strikingly, Ushermice receiving ASO-29 treatment have normal or elevated vestibular response thresholds when treated during a critical period between postnatal day 1 and 5, respectively. In contrast, treatment ofmice with ASO-29 treatment at P15 was minimally effective at rescuing vestibular function. Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestibular recovery to support normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at P15 despite the profound vestibular functional deficits that persist with treatment at this later time. These findings provide the first direct evidence of an effective treatment of peripheral vestibular function in amouse model of USH1C and reveal the potential for using antisense technology to treat vestibular dysfunction.",
author = "Sarath Vijayakumar and Depreux, {Frederic F.} and Jodelka, {Francine M.} and Lentz, {Jennifer J.} and Frank Rigo and Jones, {Timothy A.} and Hastings, {Michelle L.}",
year = "2017",
month = "9",
doi = "10.1093/hmg/ddx234",
language = "English (US)",
volume = "26",
pages = "3482--3494",
journal = "Human Molecular Genetics",
issn = "0964-6906",
publisher = "Oxford University Press",
number = "18",

}

TY - JOUR

T1 - Rescue of peripheral vestibular function in Usher syndrome mice using a splice-switching antisense oligonucleotide

AU - Vijayakumar, Sarath

AU - Depreux, Frederic F.

AU - Jodelka, Francine M.

AU - Lentz, Jennifer J.

AU - Rigo, Frank

AU - Jones, Timothy A.

AU - Hastings, Michelle L.

PY - 2017/9

Y1 - 2017/9

N2 - Usher syndrome type 1C (USH1C/harmonin) is associated with profound retinal, auditory and vestibular dysfunction. We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically improves auditory function and balance behavior inmice homozygous for the harmonin mutation Ush1c c.216G > A following a single systemic administration. The findings were suggestive of improved vestibular function; however, no direct vestibular assessment wasmade. Here, we measured vestibular sensory evoked potentials (VsEPs) to directly assess vestibular function in Ushermice. We report that VsEPs are absent or abnormal in Ushermice, indicating profound loss of vestibular function. Strikingly, Ushermice receiving ASO-29 treatment have normal or elevated vestibular response thresholds when treated during a critical period between postnatal day 1 and 5, respectively. In contrast, treatment ofmice with ASO-29 treatment at P15 was minimally effective at rescuing vestibular function. Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestibular recovery to support normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at P15 despite the profound vestibular functional deficits that persist with treatment at this later time. These findings provide the first direct evidence of an effective treatment of peripheral vestibular function in amouse model of USH1C and reveal the potential for using antisense technology to treat vestibular dysfunction.

AB - Usher syndrome type 1C (USH1C/harmonin) is associated with profound retinal, auditory and vestibular dysfunction. We have previously reported on an antisense oligonucleotide (ASO-29) that dramatically improves auditory function and balance behavior inmice homozygous for the harmonin mutation Ush1c c.216G > A following a single systemic administration. The findings were suggestive of improved vestibular function; however, no direct vestibular assessment wasmade. Here, we measured vestibular sensory evoked potentials (VsEPs) to directly assess vestibular function in Ushermice. We report that VsEPs are absent or abnormal in Ushermice, indicating profound loss of vestibular function. Strikingly, Ushermice receiving ASO-29 treatment have normal or elevated vestibular response thresholds when treated during a critical period between postnatal day 1 and 5, respectively. In contrast, treatment ofmice with ASO-29 treatment at P15 was minimally effective at rescuing vestibular function. Interestingly, ASO-29 treatment at P1, P5 or P15 resulted in sufficient vestibular recovery to support normal balance behaviors, suggesting a therapeutic benefit to balance with ASO-29 treatment at P15 despite the profound vestibular functional deficits that persist with treatment at this later time. These findings provide the first direct evidence of an effective treatment of peripheral vestibular function in amouse model of USH1C and reveal the potential for using antisense technology to treat vestibular dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=85032868752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032868752&partnerID=8YFLogxK

U2 - 10.1093/hmg/ddx234

DO - 10.1093/hmg/ddx234

M3 - Article

C2 - 28633508

AN - SCOPUS:85032868752

VL - 26

SP - 3482

EP - 3494

JO - Human Molecular Genetics

JF - Human Molecular Genetics

SN - 0964-6906

IS - 18

ER -